MX2023005618A - Plataforma de levadura para la produccion de vacunas. - Google Patents

Plataforma de levadura para la produccion de vacunas.

Info

Publication number
MX2023005618A
MX2023005618A MX2023005618A MX2023005618A MX2023005618A MX 2023005618 A MX2023005618 A MX 2023005618A MX 2023005618 A MX2023005618 A MX 2023005618A MX 2023005618 A MX2023005618 A MX 2023005618A MX 2023005618 A MX2023005618 A MX 2023005618A
Authority
MX
Mexico
Prior art keywords
production
methods
yeast
recombinant yeast
vaccines
Prior art date
Application number
MX2023005618A
Other languages
English (en)
Inventor
Karin Breunig
Constance Mehlgarten
René Zabel
Volker Franke
Carolin Kleindienst
Original Assignee
Serymun Yeast Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serymun Yeast Gmbh filed Critical Serymun Yeast Gmbh
Publication of MX2023005618A publication Critical patent/MX2023005618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a la provisión de células de levadura recombinante para la expresión eficiente y estable de transgenes, preferentemente para la expresión de uno o más polipéptidos inmunogénicos derivados de un patógeno. La invención se refiere además a composiciones de vacunas que comprenden dichas células de levadura recombinante, usos de dichas células de levadura recombinante en procedimientos de vacunación y procedimientos de producción de una vacuna de levadura completa que comprende al menos una célula de levadura recombinante diploide de la invención. Además, se abarcan procedimientos para la provisión de una célula de levadura diploide a partir de una cepa de levadura de tipo salvaje.
MX2023005618A 2020-11-13 2021-11-12 Plataforma de levadura para la produccion de vacunas. MX2023005618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207352.4A EP4001417A1 (en) 2020-11-13 2020-11-13 Yeast platform for the production of vaccines
PCT/EP2021/081604 WO2022101456A1 (en) 2020-11-13 2021-11-12 Yeast platform for the production of vaccines

Publications (1)

Publication Number Publication Date
MX2023005618A true MX2023005618A (es) 2023-08-04

Family

ID=73448813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005618A MX2023005618A (es) 2020-11-13 2021-11-12 Plataforma de levadura para la produccion de vacunas.

Country Status (5)

Country Link
EP (2) EP4001417A1 (es)
KR (1) KR20230119635A (es)
CA (1) CA3197962A1 (es)
MX (1) MX2023005618A (es)
WO (1) WO2022101456A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044866A1 (en) * 2001-08-15 2003-03-06 Charles Boone Yeast arrays, methods of making such arrays, and methods of analyzing such arrays
US20150147774A1 (en) * 2013-11-22 2015-05-28 National University Of Singapore Expression construct for yeast and a method of using the construct
US10787661B2 (en) * 2014-10-30 2020-09-29 The Board Of Trustees Of The Leland Stanford Junior University Scalable method for isolation and sequence-verification of oligonucleotides from complex libraries
CN105087406B (zh) * 2015-07-22 2019-03-05 天津大学 一种重组酵母菌株及其构建方法和应用
WO2018220113A1 (en) * 2017-06-02 2018-12-06 Firmenich Sa Method for producing albicanol and/or drimenol
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis

Also Published As

Publication number Publication date
KR20230119635A (ko) 2023-08-16
EP4001417A1 (en) 2022-05-25
CA3197962A1 (en) 2022-05-19
EP4244363A1 (en) 2023-09-20
WO2022101456A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CN101802199B (zh) 用于α病毒结构蛋白表达的无启动子盒
EP1773403B1 (en) Alphavirus-based adjuvants
KR101518309B1 (ko) 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
García et al. Therapeutic vaccines against HIV infection
Weger-Lucarelli et al. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice
NZ589812A (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
CA2777744C (en) Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
TW200637910A (en) Recombinant BCG strains with enhanced ability to escape the endosome
PH12021550029A1 (en) Adenovirus-vectored vaccine for preventing sars-cov-2 infection
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
WO2017129765A1 (en) Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
WO2005115448A3 (en) Multi plasmid system for the production of influenza virus
TWI769467B (zh) 用作b型肝炎病毒(hbv)疫苗之自我複製rna分子及其用途
Gergen et al. mRNA-based vaccines and mode of action
MX2023005618A (es) Plataforma de levadura para la produccion de vacunas.
NO347468B1 (no) Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering.
Ahata et al. CCHFV vaccine development, current challenges, limitations, and future directions
Xu et al. Evaluation of a chimeric multi-epitope-based DNA vaccine against subgroup J avian leukosis virus in chickens
Loomis et al. Gene-based vaccine approaches for respiratory syncytial virus
US20130280215A1 (en) Mva vectors expressing polypeptides and having high level production in certain cell lines
WO2012138754A3 (en) Mycobacterial vaccine vectors and methods of using the same
JP2023166412A (ja) 一価及び多価サブユニット予防ワクチン製造のために最適化した、酵母クルイベロマイセス・ラクティスベースの宿主／ベクターシステム
DE60143810D1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden